Cerevel Therapeutics Hldg Analyst Ratings
Cerevel Therapeutics Hldg Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 11.26% | Mizuho | $29 → $25 | Maintains | Neutral |
| 08/03/2023 | 86.92% | Morgan Stanley | $46 → $42 | Maintains | Overweight |
| 08/03/2023 | 37.96% | B of A Securities | $36 → $31 | Downgrades | Buy → Neutral |
| 08/03/2023 | 82.47% | HC Wainwright & Co. | $45 → $41 | Maintains | Buy |
| 05/23/2023 | 33.51% | Goldman Sachs | $31 → $30 | Maintains | Neutral |
| 05/08/2023 | 29.06% | Mizuho | $26 → $29 | Maintains | Neutral |
| 05/04/2023 | 33.51% | Wells Fargo | → $30 | Upgrades | Equal-Weight → Overweight |
| 04/10/2023 | — | TD Cowen | Initiates Coverage On | → Outperform | |
| 04/03/2023 | 100.27% | HC Wainwright & Co. | → $45 | Reiterates | → Buy |
| 03/17/2023 | 29.06% | JP Morgan | $40 → $29 | Downgrades | Overweight → Neutral |
| 03/16/2023 | -2.09% | Berenberg | → $22 | Reinstates | → Hold |
| 03/09/2023 | 15.71% | Mizuho | $28 → $26 | Maintains | Neutral |
| 02/23/2023 | 78.02% | Morgan Stanley | $50 → $40 | Maintains | Overweight |
| 02/23/2023 | 100.27% | HC Wainwright & Co. | $48 → $45 | Maintains | Buy |
| 02/23/2023 | 33.51% | Wells Fargo | $38 → $30 | Downgrades | Overweight → Equal-Weight |
| 02/22/2023 | 37.96% | Goldman Sachs | $28 → $31 | Maintains | Neutral |
| 12/06/2022 | 78.02% | JP Morgan | $49 → $40 | Maintains | Overweight |
| 11/10/2022 | 24.61% | Mizuho | $32 → $28 | Maintains | Neutral |
| 11/09/2022 | 113.62% | HC Wainwright & Co. | $50 → $48 | Maintains | Buy |
| 11/01/2022 | 78.02% | Loop Capital | → $40 | Initiates Coverage On | → Buy |
| 10/20/2022 | 73.56% | B of A Securities | → $39 | Initiates Coverage On | → Buy |
| 09/29/2022 | 82.47% | Cantor Fitzgerald | → $41 | Initiates Coverage On | → Overweight |
| 09/26/2022 | 69.11% | Wells Fargo | → $38 | Initiates Coverage On | → Overweight |
| 09/21/2022 | 24.61% | Goldman Sachs | $24 → $28 | Maintains | Neutral |
| 09/13/2022 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 08/23/2022 | 42.41% | Mizuho | $27 → $32 | Maintains | Neutral |
| 08/22/2022 | 122.52% | Morgan Stanley | $39 → $50 | Maintains | Overweight |
| 08/09/2022 | 140.32% | Stifel | $50 → $54 | Maintains | Buy |
| 08/03/2022 | 20.16% | Mizuho | $30 → $27 | Maintains | Neutral |
| 07/07/2022 | 33.51% | Mizuho | → $30 | Initiates Coverage On | → Neutral |
| 05/24/2022 | -10.99% | Goldman Sachs | $28 → $20 | Maintains | Neutral |
| 02/15/2022 | 20.16% | Goldman Sachs | → $27 | Initiates Coverage On | → Neutral |
| 01/05/2022 | 122.52% | JP Morgan | → $50 | Initiates Coverage On | → Overweight |
| 12/16/2021 | 122.52% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 09/07/2021 | 73.56% | Morgan Stanley | $27 → $39 | Maintains | Overweight |
| 06/18/2021 | 20.16% | Morgan Stanley | → $27 | Initiates Coverage On | → Overweight |
| 12/10/2020 | 6.81% | Goldman Sachs | → $24 | Initiates Coverage On | → Buy |
| 11/23/2020 | -19.89% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 11/09/2020 | -24.34% | Stifel | → $17 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/07/2023 | 11.26% | 瑞穗 | $29→$25 | 維護 | 中性 |
| 08/03/2023 | 86.92% | 摩根士丹利 | $46→$42 | 維護 | 超重 |
| 08/03/2023 | 37.96% | B of A證券 | $36→$31 | 評級下調 | 購買→中性 |
| 08/03/2023 | 82.47% | HC Wainwright公司 | $45→$41 | 維護 | 買 |
| 2023年05月23日 | 33.51% | 高盛 | $31→$30 | 維護 | 中性 |
| 05/08/2023 | 29.06% | 瑞穗 | $26→$29 | 維護 | 中性 |
| 05/04/2023 | 33.51% | 富國銀行 | →$30 | 升級 | 等重→超重 |
| 04/10/2023 | - | TD Cowen | 開始承保 | →跑贏大盤 | |
| 04/03/2023 | 100.27% | HC Wainwright公司 | →$45 | 重申 | →購買 |
| 03/17/2023 | 29.06% | 摩根大通 | $40→$29 | 評級下調 | 超重→中性 |
| 03/16/2023 | -2.09% | 貝倫伯格 | →$22 | 恢復 | →保留 |
| 03/09/2023 | 15.71% | 瑞穗 | $28→$26 | 維護 | 中性 |
| 02/23/2023 | 78.02% | 摩根士丹利 | $50→$40 | 維護 | 超重 |
| 02/23/2023 | 100.27% | HC Wainwright公司 | $48→$45 | 維護 | 買 |
| 02/23/2023 | 33.51% | 富國銀行 | $38→$30 | 評級下調 | 超重→等重 |
| 02/22/2023 | 37.96% | 高盛 | $28→$31 | 維護 | 中性 |
| 12/06/2022 | 78.02% | 摩根大通 | $49→$40 | 維護 | 超重 |
| 2022年11月10日 | 24.61% | 瑞穗 | $32→$28 | 維護 | 中性 |
| 11/09/2022 | 113.62% | HC Wainwright公司 | $50→$48 | 維護 | 買 |
| 11/01/2022 | 78.02% | 環路資本 | →$40 | 開始承保 | →購買 |
| 10/20/2022 | 73.56% | B of A證券 | →$39 | 開始承保 | →購買 |
| 09/29/2022 | 82.47% | 康託·菲茨傑拉德 | →$41 | 開始承保 | →超重 |
| 09/26/2022 | 69.11% | 富國銀行 | →$38 | 開始承保 | →超重 |
| 2022/09/21 | 24.61% | 高盛 | $24→$28 | 維護 | 中性 |
| 09/13/2022 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 2022年08月23日 | 42.41% | 瑞穗 | $27→$32 | 維護 | 中性 |
| 2022/08/22 | 122.52% | 摩根士丹利 | $39→$50 | 維護 | 超重 |
| 08/09/2022 | 140.32% | Stifel | $50→$54 | 維護 | 買 |
| 08/03/2022 | 20.16% | 瑞穗 | $30→$27 | 維護 | 中性 |
| 07/07/2022 | 33.51% | 瑞穗 | →$30 | 開始承保 | →中性 |
| 2022年05月24日 | -10.99% | 高盛 | $28→$20 | 維護 | 中性 |
| 02/15/2022 | 20.16% | 高盛 | →$27 | 開始承保 | →中性 |
| 01/05/2022 | 122.52% | 摩根大通 | →$50 | 開始承保 | →超重 |
| 12/16/2021 | 122.52% | HC Wainwright公司 | →$50 | 開始承保 | →購買 |
| 09/07/2021 | 73.56% | 摩根士丹利 | $27→$39 | 維護 | 超重 |
| 06/18/2021 | 20.16% | 摩根士丹利 | →$27 | 開始承保 | →超重 |
| 12/10/2020 | 6.81% | 高盛 | →$24 | 開始承保 | →購買 |
| 11/23/2020 | -19.89% | 傑富瑞 | →$18 | 開始承保 | →購買 |
| 11/09/2020 | -24.34% | Stifel | →$17 | 開始承保 | →購買 |
What is the target price for Cerevel Therapeutics Hldg (CERE)?
Cerevel Treateutics Hldg(CERE)的目標價格是多少？
The latest price target for Cerevel Therapeutics Hldg (NASDAQ: CERE) was reported by Mizuho on August 7, 2023. The analyst firm set a price target for $25.00 expecting CERE to rise to within 12 months (a possible 11.26% upside). 28 analyst firms have reported ratings in the last year.
瑞穗於2023年8月7日報道了Cerevel Treateutics Hldg(納斯達克：CEE)的最新目標價。這家分析公司將目標價定為25美元，預計CERE將在12個月內升至(可能上漲11.26%)。去年有28家分析公司公佈了評級。
What is the most recent analyst rating for Cerevel Therapeutics Hldg (CERE)?
Cerevel Treateutics Hldg(CERE)最近的分析師評級是什麼？
The latest analyst rating for Cerevel Therapeutics Hldg (NASDAQ: CERE) was provided by Mizuho, and Cerevel Therapeutics Hldg maintained their neutral rating.
瑞穗提供了對Cerevel Treateutics Hldg(納斯達克代碼：CEE)的最新分析師評級，Cerevel Treateutics Hldg維持其中性評級。
When is the next analyst rating going to be posted or updated for Cerevel Therapeutics Hldg (CERE)?
Cerevel Treateutics Hldg(CERE)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cerevel Therapeutics Hldg, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cerevel Therapeutics Hldg was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Cerevel Treateutics Hldg的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Cerevel Treateutics Hldg的上一次評級是在2023年8月7日提交的，因此您應該預計下一次評級將在2024年8月7日左右提供。
Is the Analyst Rating Cerevel Therapeutics Hldg (CERE) correct?
分析師對Cerevel Treateutics Hldg(CERE)的評級正確嗎？
While ratings are subjective and will change, the latest Cerevel Therapeutics Hldg (CERE) rating was a maintained with a price target of $29.00 to $25.00. The current price Cerevel Therapeutics Hldg (CERE) is trading at is $22.47, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Cerevel Treateutics Hldg(CERE)評級保持不變，目標價在29.00美元至25.00美元之間。Cerevel Treateutics Hldg(CERE)目前的交易價格為22.47美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。